Central nervous system (CNS) manifestations are rare complications of relapsing polychondritis (RP). The majority of patients respond well to glucocorticoid therapy, but need to maintain it. Some patients are refractory to initial glucocorticoid therapy and to additional immunosuppressants, and end up with an outcome worse than at therapy initiation. The standardized therapeutic protocol for this condition has not been established. The effects of anti-tumor necrosis factor (TNF) -α agents have been reported recently. We experienced a patient with RP and limbic encephalitis who was refractory to initial high-dose glucocorticoid, but subsequently responded to infliximab and did not show deterioration of signs and symptoms after stopping therapy. We report this case together with a systematic literature review. This is the first case report of RP with CNS manifestations successfully treated by an anti-TNF-α agent without recurrence after discontinuation.
INTRODUCTION
Relapsing polychondritis (RP) is an uncommon disorder of unknown etiology that is characterized by recurrent and progressive inflammation of cartilaginous structures. A minority of patients with RP develop central nervous system (CNS) manifestations, 1) and limbic encephalitis has also been reported. [1] [2] [3] [4] [5] Glucocorticoid has been used as the first-line therapeutic agent, but a standardized second-line therapeutic protocol for RP with CNS manifestations has not been established. The effects of anti-tumor necrosis factor (TNF) -α agents have been reported recently. 5, 9) We report a patient with limbic encephalitis associated with RP who was refractory to initial high-dose glucocorticoid therapy, but subsequently responded to infliximab and discontinued therapy without recurrence. We also reviewed cases of RP with CNS manifestations using PubMed with regard to clinical manifestations and treatment.
CASE PRESENTATION
A 58-year-old Japanese male architect was brought to our institution by his wife, presenting with amnesia, disorientation, emotional liability and urinary incontinence. One year prior to admission, he had bilateral ear pain with swelling and erythema which improved without any treatment over a 4-week period. Nine months prior to admission, he experienced iritis and scleritis in addition to recurrent pain in bilateral auricles. Subsequent biopsy of the left auricle revealed infiltration of inflammatory cells in the perichondrium (Fig. 1) . Diagnosis of RP was made based on McAdam's criteria, modified by Damiani and Levine. 23, 24) No other organs were affected. Inflammation of bilateral auricles disappeared without any treatment, while iritis and scleritis were controlled by topical glucocorticoid therapy. Around 2 months prior to admission, he showed amnesia with gradual progression. One month prior to admission, he developed difficulty with drawing architectural drafts and finding his way home, together with emotional liability and urinary incontinence. Past medical history revealed well-controlled diabetes mellitus by diet and dipeptidyl peptidase-4 inhibitor (HbA1c was 6.4 to 6.7%).
On admission, his body temperature was 36.7°C, blood pressure was 112/66 mmHg and heart rate was 68 beats per minute. Physical examination revealed flared ears. Head, eye, ear, nose, chest and abdominal examinations were unremarkable. Neurological examination revealed poor tandem gait and poor finger-nose-finger test, but other examinations such as the cranial nerve, sensory and motor systems were unremarkable. He was euphoric and disoriented. His Mini-Mental States Examination (MMSE) result was 16 out of 30. Complete blood cell count, serum chemistry screening and endocrine function were unremarkable. Antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, rheumatoid factor, anti-thyroid peroxydase antibody, antithyroglobulin antibody, urinalysis and serological tests for human immunodeficiency virus (HIV) Fig. 1 (Fig. 2-A, B) . Diffusion weighted image, fluid-attenuated inversion recovery image (FLAIR) and gadolinium enhancement showed no abnormality. Electroencephalogram showed diffuse dominant theta waves with no spike.
Considering his clinical symptoms like emotional lability and amnesia, limbic system atrophy in MRI and increased number of CSF cells limbic encephalitis was diagnosed. Because other causes such as HIV encephalitis, herpes simplex encephalitis, tumor-associated limbic encephalitis or Hashimoto encephalopathy were ruled out, limbic encephalitis associated with RP was diagnosed, clinically. A course of intravenous 1 g methylprednisolone for 3 days was administered, followed by oral prednisolone 1 mg/kg per day. His cognitive function improved temporarily, but worsened again (Fig. 3 ). Subsequently infliximab 3 mg/kg was added to the prednisolone. His head MRI had no change but MMSE score was improved gradually, ataxia disappeared through 4 doses of infliximab over a 3-month period, and problematic behavior disappeared. Because of his stable condition as well as the high cost of infliximab, he and his wife refused further infliximab therapy. His condition continued to be stable without infliximab. Prednisolone was tapered down over a 16-month period and finally stopped. The patient was followed up for an additional 9 months after stopping prednisolone without recurrence (Fig. 3) . At the end, he could continue active daily living independently, but could not resume his work. DISCUSSION RP, a rare episodic and progressive inflammatory disease presumed to have autoimmune etiology, was first described in 1923. 25) RP affects cartilage in multiple organs, such as the ear, nose, larynx, trachea, bronchi, and joints. 25) In addition, it can affect proteoglycan-rich tissues such as the eyes, aorta, heart and skin. 25) The diagnosis of RP is usually made on the basis of clinical findings. 25) McAdam criteria 23) modified by Damiani and Levine, 24) which is commonly used as a criterion to confirm the diagnosis of RP, consists of: a) at least 3 of 6 clinical criteria (bilateral auricular chondritis, nonerosive seronegative inflammatory polyarthritis, nasal chondritis, ocular inflammation, respiratory chondritis and audiovestibular damage); b) 1 or more of the previously-mentioned clinical criteria and biopsy confirmation of cartilage inflammation; or c) chondritis at 2 or more separate anatomic locations with response to steroids and/or dapsone. This case fits criterion b).
RP with CNS manifestations is rare. 8, 22) We searched MEDLINE in March 2014 using ("Polychondritis, Relapsing" [Mesh] OR "Relapsing polychondritis") AND ("Encephalitis" [Mesh] OR "Limbic Encephalitis" [Mesh] or encephalitis or encephalopathy or "Limbic Encephalitis" OR "Meningoencephalitis" [Mesh] OR Meningoencephalitis or "nervous system") as keywords. We retrieved a total of 54 articles, 26 of them including 31 cases that met inclusion criteria (case report or case series written in English or Japanese) ( Table 1) . [26] [27] [28] As shown in Table 1 , 28 out of 31 patients have been treated with a high dose of glucocorticoid. Twenty-two out of those 28 patients had symptoms which were well-controlled by initial therapy, but only one could discontinue glucocorticoid therapy. 19) Six patients were refractory to initial glucocorticoid therapy. 3, 4, 7, 9, 11, 12) Additional therapy (cyclophosphamide, intravenous immune globulin, tacrolimus, plasmapheresis, methotrexate and cyclosporin) showed no remarkable effect 3, 4, 7, 11, 12) Only one who was treated with inflixmab 9) had a good outcome, so we chose infliximab as a second-line agent. This is the first case report of RP with CNS manifestations treated with an anti-TNF-α agent who did not show deterioration of signs and symptoms after stopping therapy.
Infliximab may be a good choice for RP with CNS manifestation refractory to initial glucocorticoid therapy. 9) Infliximab has a large molecular weight, so it is impossible for it to permeate the blood-brain barrier. Then why does it work? One potential explanation is that breakdown of the blood-brain barrier by inflammation may permit infliximab to access cerebral parenchyma, resulting in the suppression of TNF-α mediated inflammatory processes. 29) Although theoretically it may be reasonable to stop infliximab when neurologic symptoms are stable, if breakdown of the blood-brain barrier by inflammation is important for the effect of infliximab, it would be wise to closely observe the clinical course when discontinuing infliximab.
CONCLUSION
Anti-TNF-α agents may be a treatment of choice for RP with CNS manifestations refractory to initial glucocorticoid therapy. In addition, anti-TNF-α agents may be discontinued, but it would be prudent to closely observe the clinical course when stopping infliximab.
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